GoAI
Get started
SCYNEXIS, Inc. logo

SCYNEXIS, Inc.

SCYX

NASDAQHealthcareMedical - Pharmaceuticals

Open in GoAI

Previous close

$5.10

−$0.12 · -2.30%

Aug 21, 4:00 PM ET

SCYX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

47

Fair Value

Momentum

26

Weakening

Sentiment

61

Bullish

Risk resilience

28

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

Industry
Medical - Pharmaceuticals
Sector
Healthcare
Headquarters
US
CEO
David Angulo
Listed since
May 2, 2014
Employees
18

Market position

Day range

Current $5.10

52-week range

Current $5.10

Open
$5.29
Previous close
$5.22
Volume
35.18K
0.29× average
Average volume
121.52K
Average daily volume
Market cap
32.07M USD
Beta
1.1
Market reference 1
50-day average
$4.4442
+14.76% above average
200-day average
$5.6718
-10.08% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
12.5M USD
P/E (TTM)
-2.77×
P/B (TTM)
0.9×
P/S (TTM)
1.67×
EV / EBITDA
-1.54×
Earnings yield
-27.26%
Free cash flow yield
-16.73%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
100.00%
Operating margin
-117.61%
Net margin
-53.27%
Return on equity
-17.44%
Return on assets
-14.58%
Return on invested capital
-29.89%

Financial health

Debt / equity
0.03×
Current ratio
7.04×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends278%-435%-1149%-1863%Gross margin, FY2021: 97.63%Gross margin, FY2022: 87.66%Gross margin, FY2023: 88.85%Gross margin, FY2024: 100.00%Gross margin, FY2025: 100.00%Operating margin, FY2021: -462.19%Operating margin, FY2022: -1684.48%Operating margin, FY2023: 51.85%Operating margin, FY2024: -990.84%Operating margin, FY2025: -78.03%Net margin, FY2021: -249.68%Net margin, FY2022: -1233.73%Net margin, FY2023: 47.84%Net margin, FY2024: -568.29%Net margin, FY2025: -41.79%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 97.63%. Gross margin FY2022 87.66%. Gross margin FY2023 88.85%. Gross margin FY2024 100.00%. Gross margin FY2025 100.00%. Operating margin FY2021 -462.19%. Operating margin FY2022 -1684.48%. Operating margin FY2023 51.85%. Operating margin FY2024 -990.84%. Operating margin FY2025 -78.03%. Net margin FY2021 -249.68%. Net margin FY2022 -1233.73%. Net margin FY2023 47.84%. Net margin FY2024 -568.29%. Net margin FY2025 -41.79%.

Income trends

Revenue

20.6M USD+449.95%

Operating income

−16.07M USD+56.69%

Net income

−8.61M USD+59.56%
Income trends across reported periods162.73M USD72.37M USD−17.99M USD−108.35M USDRevenue, FY2021: 13.16M USDRevenue, FY2022: 5.09M USDRevenue, FY2023: 140.14M USDRevenue, FY2024: 3.75M USDRevenue, FY2025: 20.6M USDOperating income, FY2021: −60.84M USDOperating income, FY2022: −85.76M USDOperating income, FY2023: 72.67M USDOperating income, FY2024: −37.12M USDOperating income, FY2025: −16.07M USDNet income, FY2021: −32.87M USDNet income, FY2022: −62.81M USDNet income, FY2023: 67.04M USDNet income, FY2024: −21.29M USDNet income, FY2025: −8.61M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 13.16M USD. Revenue FY2022 5.09M USD. Revenue FY2023 140.14M USD. Revenue FY2024 3.75M USD. Revenue FY2025 20.6M USD. Operating income FY2021 −60.84M USD. Operating income FY2022 −85.76M USD. Operating income FY2023 72.67M USD. Operating income FY2024 −37.12M USD. Operating income FY2025 −16.07M USD. Net income FY2021 −32.87M USD. Net income FY2022 −62.81M USD. Net income FY2023 67.04M USD. Net income FY2024 −21.29M USD. Net income FY2025 −8.61M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue20.6M USD3.75M USD140.14M USD5.09M USD13.16M USD
Cost of goods sold——15.62M USD628K USD312K USD
Gross profit20.6M USD3.75M USD124.52M USD4.46M USD12.85M USD
Research and development22.28M USD26.41M USD30.93M USD27.26M USD23.77M USD
Selling, general, and administrative14.4M USD14.46M USD20.92M USD62.96M USD49.92M USD
Operating expenses36.68M USD40.86M USD51.85M USD90.22M USD73.69M USD
Interest income2.18M USD4.29M USD3.95M USD1.42M USD24K USD
Interest expense173K USD2.55M USD6.12M USD6.79M USD3.96M USD
Depreciation and amortization312K USD1.73M USD580K USD813K USD379K USD
Operating income−16.07M USD−37.12M USD72.67M USD−85.76M USD−60.84M USD
Net income−8.61M USD−21.29M USD67.04M USD−62.81M USD−32.87M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
-802.89%
11 comparable reports
Latest EPS result
0.63
Estimate -0.51 · Beat by 224.34%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates2.430.36-1.72-3.79Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 12, 2025: actual -0.72, estimate -0.02, surprise -3500.00%, Miss. Q2 2025, reported May 16, 2025: actual -0.88, estimate -1.55, surprise +43.10%, Beat. Q3 2025, reported Aug 14, 2025: actual -1.12, estimate -1.52, surprise +26.32%, Beat. Q4 2025, reported Nov 5, 2025: actual -1.36, estimate -1.6, surprise +15.00%, Beat. Q1 2026, reported Mar 4, 2026: actual 2, estimate 1.01, surprise +98.02%, Beat. Q2 2026, reported May 11, 2026: actual -3.36, estimate -0.8, surprise -320.00%, Miss. Q3 2026, reported Aug 10, 2026: actual 0.63, estimate -0.507, surprise +224.34%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate -0.613, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates20.13M13.44M6.75M65.45KQ1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26EstimateQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 12, 2025: actual 977K USD, estimate 10.19M USD, surprise -90.41%, Miss. Q2 2025, reported May 16, 2025: actual 257K USD, estimate 137K USD, surprise +87.59%, Beat. Q3 2025, reported Aug 14, 2025: actual 1.36M USD, estimate 154K USD, surprise +785.71%, Beat. Q4 2025, reported Nov 5, 2025: actual 334K USD, estimate 133.33K USD, surprise +150.50%, Beat. Q1 2026, reported Mar 4, 2026: actual 18.65M USD, estimate 8.1M USD, surprise +130.20%, Beat. Q2 2026, reported May 11, 2026: actual —, estimate 77K USD, surprise —, Comparison unavailable. Q3 2026, reported Aug 10, 2026: actual 235K USD, estimate 80.33K USD, surprise +192.53%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 98K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

14 ratings
Strong buy00%
Buy1393%
Hold17%
Sell00%
Strong sell00%

Corporate actions

Corporate action history

Stock split

Effective Jun 1, 2026

1:8

Stock split

Effective Jul 17, 2020

1:10

SCYX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding SCYX

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
1.41M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
620.46K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
EA Bridgeway Omni Small-Cap Value ETF logoEA Bridgeway Omni Small-Cap Value ETFBSVO
Market value
80K
Weight
—
AUM
1.71B USD
Expense ratio
0.47%
Price / 1D
$29.62+0.85%
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
27.09K
Weight
0.00%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$83.02+0.73%
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
25.22K
Weight
0.00%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.95+0.73%

Continue in GoAI

Research SCYX

research.disclaimer